Comparative evaluation of psychopharmacotherapy of atypical depression in bipolar and recurrent affective disorder, psychogenic depression

Objective: to evaluate the treatment effectiveness for atypical depression (AtD) depending on its nosology: in bipolar affective disorder (BAD), recurrent depressive disorder (RDD) and psychogenic depression (PD).

Patients and methods. A total of 250 patients with depression were screened, of which 77 patients with symptoms of AtD were enrolled in the study, 35 of them with BAD, 18 with RDD, and 24 with PD. Patients in all three groups received an antidepressant (AD) or a mood stabilizer (MS) monotherapy, or a combination of AD and antipsychotic (A), AD and A, MS and A, as well as a combination of AD, A and MS. The patients' condition was assessed clinically using a specially designed questionnaire and MADRS and CGI scales at the baseline and the 2nd, 3rd, 4th, 6th, 12th weeks of treatment. Quality of life satisfaction was assessed with the Q-LES-Q-SF (Scoring the Quality-of-Life Enjoyment and Satisfaction Questionnaire) scale at the treatment onset and after the 12th week of treatment.

Results and discussion. Treatment regimens that included AD were the most eff in all groups of patients with AtD. The proportion of responders among those who received AD for bipolar disorder (75% or more) was significantly higher than among those who did not receive it (˂50%). In the RDD and PD groups, patients responded significantly better to AD monotherapy (RDD – 93.2%; PD – 91.5%) compared to other regimens. Agomelatine was the most frequently used (31.8%) and effective AD in all groups. Also, escitalopram, vortioxetine, and venlafaxine (p˂0.05) showed high efficacy, good tolerance, and absence of side effects that aggravate the main symptoms that characterize AtD. Among the antipsychotics in combination with AD, sulpiride was significantly more effective in patients with PD (p˂0.05). The highest rates of quality of life satisfaction were achieved in the BAD group, the lowest – in patients with PD (p˂0.05), which indirectly indicates the quality of remission, which is determined not only by the degree of reduction of depressive symptoms but also by the patients' subjective perception of their mental state.

Conclusion. The inclusion of AD in the AtD treatment regimen significantly increases its effectiveness in patients of all groups, including BAD. AtD treatment should be administered not only taking into account its clinical signs and severity, but also depending on the nosology of the disease, the characteristics of its course. During drug administration, it is necessary to consider the spectrum of side effects, especially those that increase the symptoms of AtD itself. 

1. Huston PE, Locker LM. Manic-depressive psychosis; course when treated and untreated with electric shock. Arch Neurol Psychiatry. 1948 Jul;60(1):37-48.

2. West ED, Dally PJ. Effect of iproniazid in depressive syndromes. Br Med J. 1959 Jun 13;1(5136):1491-4. doi: 10.1136/bmj.1.5136.1491

3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington: American Psychiatric Publishing; 2013.

4. Husain MM, McClintock SM, Rush AJ, et al. The efficacy of acute electroconvulsive therapy in atypical depression. J Clin Psychiatry. 2008 Mar;69(3):406-11. doi: 10.4088/jcp.v69n0310

5. Klein DF. The treatment of atypical depression. Eur Psichiatry. 1993;8(5):251-5.

6. Mosolov SN. Trevozhnyye i depressivnyye rasstroystva: komorbidnost' i terapiya [Anxiety and depressive disorders: comorbidity and therapy]. Moscow: LLC “AMA-PRESS”; 2009. P. 31-3 (In Russ.).

7. Stewart J. Atypical depression: history and future. Psychiatr Ann. 2014;44(12):557-62.

8. Rethorst CD, Tu J, Carmody TJ, et al. Atypical depressive symptoms as a predictor of treatment response to exercise in Major Depressive Disorder. J Affect Disord. 2016 Aug;200:156-8. doi: 10.1016/j.jad.2016.01.052. Epub 2016 Apr 23.

9. Cooney G, Dwan K, Mead G. Exercise for depression. JAMA. 2014 Jun 18;311(23):2432-3. doi: 10.1001/jama.2014.4930

10. Josefsson T, Lindwall M, Archer T. Physical exercise intervention in depressive disorders: meta-analysis and systematic review. Scand J Med Sci Sports. 2014 Apr;24(2):259-72. doi: 10.1111/sms.12050. Epub 2013 Jan 30.

11. Rethorst CD, Sunderajan P, Greer TL, et al. Does exercise improve self-reported sleep quality in non-remitted major depressive disorder? Psychol Med. 2013 Apr;43(4):699-709. doi: 10.1017/S0033291712001675. Epub 2012 Aug 29.

12. Rethorst CD, Wipfli BM, Landers DM. The antidepressive effects of exercise: a metaanalysis of randomized trials. Sports Med. 2009;39(6):491-511. doi: 10.2165/00007256-200939060-00004

13. Silveira H, Moraes H, Oliveira N, et al. Physical exercise and clinically depressed patients: a systematic review and meta-analysis. Neuropsychobiology. 2013;67(2):61-8. doi: 10.1159/000345160. Epub 2013 Jan 4.

14. Weinstock LM, Munroe M, Brown IM. Behavioral activation for the treatment of atypical depression:a pilot open trial. Behav Modif. 2011 Jul;35(4):403-24. doi: 10.1177/0145445511405646. Epub 2011 Apr 19.

15. Fournier JC, DeRubeis RJ, Hollon SD, et al. Differential change in specific depressive symptoms during antidepressant medication or cognitive therapy. Behav Res Ther. 2013 Jul;51(7):392-8. doi: 10.1016/j.brat.2013.03.010. Epub 2013 Apr 12.

16. Barber JP, DeRubeis RJ. On second thought: Where the action is in cognitive therapy for depression. Cogn Ther Res. 1989;13:441- 57.

17. Beck AT, Rush AJ, Shaw BF, Emery G. Cognitive Therapy of Depression. New York: The Guilford Press; 1979.

18. Bhar SS, Gelfand LA, Schmid SP, et al. Sequence of improvement in depressive symptoms across cognitive therapy and pharmacotherapy. J Affect Disord. 2008 Sep;110(1- 2):161-6. doi: 10.1016/j.jad.2007.12.227. Epub 2008 Feb 13.

19. DeRubeis RJ, Hollon SD, Amsterdam JD, et al. Cognitive therapy vs medications in the treatment of moderate to severe depression. Arch Gen Psychiatry. 2005 Apr;62(4):409- 16. doi: 10.1001/archpsyc.62.4.409

20. Stewart JW, Quitkin FM, Terman M, Terman JS. Is seasonal affective disorder a variant of atypical depression? Differential response to light therapy. Psychiatry Res. 1990 Aug;33(2):121-8. doi: 10.1016/0165-1781(90)90065-d

21. Pae CU, Patkar AA, Jang S, et al. Efficacy and safety of selegiline transdermal system (STS) for the atypical subtype of major depressive disorder: pooled analysis of 5 short-term, placebo-controlled trials. CNS Spectr. 2014 Aug;19(4):324-9. doi: 10.1017/S1092852913000655. Epub 2013 Oct 29.

22. Keller J, Schatzberg AF, Maj M. Current issues in the Classification of Psychotic Major Depression. Schizophr Bull. 2007 Jul;33(4):877-85. doi: 10.1093/schbul/sbm065. Epub 2007 Jun 4.

23. Maj M, Pirozzi R, Magliano L, et al. Phenomenology and prognostic significance of delusions in major depressive disorder: a 10-year prospective follow-up study. J Clin Psychiatry. 2007 Sep;68(9):1411-7. doi: 10.4088/jcp.v68n0913

24. Lonnqvist J, Sihvo S, Syvalahti E, Kiviruusu OJ. Moclobemide and fluoxetine in atypical depression: a double-blind trial. J Affect Disord. 1994 Nov;32(3):169-77. doi: 10.1016/0165-0327(94)90015-9

25. Goodwin GM, Price J, De Bodinat C, Laredo J. Emotional blunting with antidepressant treatments: A survey among depressed patients. J Affect Disord. 2017 Oct 15;221:31-5. doi: 10.1016/j.jad.2017.05.048. Epub 2017 Jun 6.

26. Romanov DV, Volel BA, Petelin DS. Approaches to therapy for depressions in neurology: prospects for the use of agomelatine. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2018;10(4):101-10. doi: 10.14412/2074-2711- 2018-4-101-110 (In Russ.).

27. Lee SH, Park YC, Yoon S, et al. Clinical implications of loudness dependence of auditory evoked potentials in patients with atypical depression. Prog Neuropsychopharmacol Biol Psychiatry. 2014 Oct 3;54:7-12. doi: 10.1016/j.pnpbp.2014.05.010. Epub 2014 May 24.

28. Tyuvina NA, Korobkova IG. Therapy for depression in bipolar affective disorder. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2016;8(2):36-43. doi: 10.14412/2074-2711-2016-2-36-43 (In Russ.).

29. Tyuvina NA, Stolyarova AE, Balabanova VV, et al. Comparative study of depression treatment in women and men with bipolar affective disorder. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2021;13(3):59-66. https://doi.org/10.14412/2074-2711-2021-3-59-66 (In Russ.).

30. Marachev MP. Efficacy of agomelatine in the treatment of atypical depression. Psikhiatriya i psikhofarmakoterapiya im. P.B. Gannushkina. 2012;14(3):25-30 (In Russ.).

31. Bobrov AS, Petrunko OV, Khamarkhanova AA, Shvetsova AV. Clinical predictors of response to Valdoxan therapy in moderate and severe depression. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2010;110(9):14 (In Russ.).

32. Ivanov SV. Valdoxan (agomelatine) in the treatment of moderate and severe nonpsychotic depression in outpatient and hospital practice. Results of the Russian multicenter study CHRONOS. Psikhiatriya i psikhofarmakoterapiya. 2009;(6):14-7 (In Russ.).

33. Avedisova AS, Marachev MP. Clinical typology of atypical depression and its relation to bipolar disorder. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2012;112(3):18-24 (In Russ.).

34. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018 Apr 7;391(10128):1357-66. doi: 10.1016/S0140-6736(17)32802-7. Epub 2018 Feb 21.

35. Maier W, Benkert O. Treatment of chronic depression with sulpiride: evidence of efficacy in placebo-controlled single case studies. Psychopharmacology. 1994 Aug;115(4):495-501. doi: 10.1007/BF02245573

36. Tsukamoto T, Asakura M, Tsuneizumi T, et al. Therapeutic effects and side effects in patients with major depression treated with sulpiride once a day. Prog Neuropsychopharmacol Biol Psychiatry. 1994 May;18(3):615-8. doi: 10.1016/0278-5846(94)90017-5